Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

John R. Asplin

TitleClinical Associate
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ennis JL, Luo D, Asplin JR, Coe FL. A laboratory-based algorithm to predict future kidney function decline in older adults with reduced estimated glomerular filtration rate?. Clin Nephrol. 2019 Sep; 92(3):113-122. PMID: 31319905.
      View in: PubMed
    2. Krieger NS, Asplin JR, Granja I, Ramos FM, Flotteron C, Chen L, Wu TT, Grynpas MD, Bushinsky DA. Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats. J Am Soc Nephrol. 2019 Jul; 30(7):1163-1173. PMID: 31101664.
      View in: PubMed
    3. Wollin DA, Davis LG, Winship BB, Carlos EC, Tom WR, Asplin JR, Kosinski AS, Scales CD, Ferrandino MN, Preminger GM, Lipkin ME. Assessment of conservative dietary management as a method for normalization of 24-h urine pH in stone formers. Urolithiasis. 2019 May 06. PMID: 31062069.
      View in: PubMed
    4. Asplin JR, Goldfarb DS. Effect of thiazolidinedione therapy on the risk of uric acid stones. Kidney Int. 2019 05; 95(5):1022-1024. PMID: 31010476.
      View in: PubMed
    5. Menezes CJ, Worcester EM, Coe FL, Asplin J, Bergsland KJ, Ko B. Mechanisms for falling urine pH with age in stone formers. Am J Physiol Renal Physiol. 2019 Jul 01; 317(7):F65-F72. PMID: 31017011.
      View in: PubMed
    6. Malieckal DA, Modersitzki F, Mara K, Enders FT, Asplin JR, Goldfarb DS. Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria. Urolithiasis. 2019 Dec; 47(6):549-555. PMID: 30980122.
      View in: PubMed
    7. Kim D, Rimer JD, Asplin JR. Hydroxycitrate: a potential new therapy for calcium urolithiasis. Urolithiasis. 2019 Aug; 47(4):311-320. PMID: 30915494.
      View in: PubMed
    8. Brown L, Luciano A, Pendergast J, Khairallah P, Anderson CAM, Sondheimer J, Hamm LL, Ricardo AC, Rao P, Rahman M, Miller ER, Sha D, Xie D, Feldman HI, Asplin J, Wolf M, Scialla JJ. Predictors of Net Acid Excretion in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2019 Aug; 74(2):203-212. PMID: 30910373.
      View in: PubMed
    9. Krieger NS, Grynpas M, VandenEynde A, Asplin JR, Frick KK, Kim MH, Ramos FM, Granja I, Bushinsky DA. Low Sodium Diet Decreases Stone Formation in Genetic Hypercalciuric Stone-Forming Rats. Nephron. 2019; 142(2):147-158. PMID: 30726853.
      View in: PubMed
    10. Ziemba JB, Gurnani R, Ludwig WW, Gorin MA, Asplin J, Matlaga BR. Individual renal unit urine sampling to identify unilateral metabolic defects?. Clin Nephrol. 2019 Feb; 91(2):87-94. PMID: 30369399.
      View in: PubMed
    11. Cheng JW, Wagner H, Asplin JR, Hodgkin G, Schlaifer A, Fargusson M, Fargusson J, Baldwin DD. The Effect of Lemonade and Diet Lemonade Upon Urinary Parameters Affecting Calcium Urinary Stone Formation. J Endourol. 2019 02; 33(2):160-166. PMID: 30585747.
      View in: PubMed
    12. Stern JM, Urban-Maldonado M, Usyk M, Granja I, Schoenfeld D, Davies KP, Agalliu I, Asplin J, Burk R, Suadicani SO. Fecal transplant modifies urine chemistry risk factors for urinary stone disease. Physiol Rep. 2019 02; 7(4):e14012. PMID: 30789675.
      View in: PubMed
    13. Patel RM, Jiang P, Asplin J, Granja I, Capretz T, Osann K, Okhunov Z, Landman J, Clayman RV. Coconut Water: An Unexpected Source of Urinary Citrate. Biomed Res Int. 2018; 2018:3061742. PMID: 30515390.
      View in: PubMed
    14. Bashir M, Meddings J, Alshaikh A, Jung D, Le K, Amin R, Ratakonda S, Sharma S, Granja I, Satti M, Asplin J, Hassan H. Enhanced gastrointestinal passive paracellular permeability contributes to the obesity-associated hyperoxaluria. Am J Physiol Gastrointest Liver Physiol. 2019 01 01; 316(1):G1-G14. PMID: 30307745.
      View in: PubMed
    15. Bergsland KJ, Coe FL, Parks JH, Asplin JR, Worcester EM. Evidence for a role of PDZ domain-containing proteins to mediate hypophosphatemia in calcium stone formers. Nephrol Dial Transplant. 2018 05 01; 33(5):759-770. PMID: 29126251.
      View in: PubMed
    16. Hinck BD, Miyaoka R, Lingeman JE, Assimos DG, Matlaga BR, Pramanik R, Asplin J, Cohen B, Monga M. Urine kidney injury markers do not increase following gastric bypass: a multi-center cross-sectional study. Can J Urol. 2018 02; 25(1):9199-9204. PMID: 29524975.
      View in: PubMed
    17. Amin R, Asplin J, Jung D, Bashir M, Alshaikh A, Ratakonda S, Sharma S, Jeon S, Granja I, Matern D, Hassan H. Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria. Kidney Int. 2018 05; 93(5):1098-1107. PMID: 29395336.
      View in: PubMed
    18. Ellison JS, Hollingsworth JM, Langman CB, Asplin JR, Schwaderer AL, Yan P, Bierlein M, Barraza MA, Defoor WR, Figueroa TE, Jackson EC, Jayanthi VR, Johnson EK, Joseph DB, Shnorhavorian M. Analyte variations in consecutive 24-hour urine collections in children. J Pediatr Urol. 2017 Dec; 13(6):632.e1-632.e7. PMID: 28739373.
      View in: PubMed
    19. Hinck BD, Ganesan V, Tarplin S, Asplin J, Granja I, Calle J, Sivalingam S, Monga M. Can a Simplified 12-Hour Nighttime Urine Collection Predict Urinary Stone Risk? Urology. 2017 Oct; 108:40-45. PMID: 28705575.
      View in: PubMed
    20. Khairallah P, Isakova T, Asplin J, Hamm L, Dobre M, Rahman M, Sharma K, Leonard M, Miller E, Jaar B, Brecklin C, Yang W, Wang X, Feldman H, Wolf M, Scialla JJ. Acid Load and Phosphorus Homeostasis in CKD. Am J Kidney Dis. 2017 Oct; 70(4):541-550. PMID: 28645705.
      View in: PubMed
    21. Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney Int Rep. 2017 Nov; 2(6):1050-1058. PMID: 29270514.
      View in: PubMed
    22. Scialla JJ, Asplin J, Wolf M. The Authors Reply. Kidney Int. 2017 06; 91(6):1518-1519. PMID: 28501306.
      View in: PubMed
    23. DeFoor W, Jackson E, Schulte M, Alam Z, Asplin J. Calcium-to-Citrate Ratio Distinguishes Solitary and Recurrent Urinary Stone Forming Children. J Urol. 2017 08; 198(2):416-421. PMID: 28365270.
      View in: PubMed
    24. Moreland AM, Santa Ana CA, Asplin JR, Kuhn JA, Holmes RP, Cole JA, Odstrcil EA, Van Dinter TG, Martinez JG, Fordtran JS. Steatorrhea and Hyperoxaluria in Severely Obese Patients Before and After Roux-en-Y Gastric Bypass. Gastroenterology. 2017 04; 152(5):1055-1067.e3. PMID: 28089681.
      View in: PubMed
    25. Scialla JJ, Asplin J, Dobre M, Chang AR, Lash J, Hsu CY, Kallem RR, Hamm LL, Feldman HI, Chen J, Appel LJ, Anderson CA, Wolf M. Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes. Kidney Int. 2017 01; 91(1):204-215. PMID: 27914710.
      View in: PubMed
    26. Ennis JL, Asplin JR. The role of the 24-h urine collection in the management of nephrolithiasis. Int J Surg. 2016 Dec; 36(Pt D):633-637. PMID: 27840312.
      View in: PubMed
    27. Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M, Karrar E, Roy-Chowdhury J, Musch M, Asplin J, Chang E, Hassan H. Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells. J Am Soc Nephrol. 2017 Mar; 28(3):876-887. PMID: 27738124.
      View in: PubMed
    28. Mulay SR, Eberhard JN, Desai J, Marschner JA, Kumar SV, Weidenbusch M, Grigorescu M, Lech M, Eltrich N, Müller L, Hans W, Hrabe de Angelis M, Vielhauer V, Hoppe B, Asplin J, Burzlaff N, Herrmann M, Evan A, Anders HJ. Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease. J Am Soc Nephrol. 2017 Mar; 28(3):761-768. PMID: 27612997.
      View in: PubMed
    29. Chung J, Granja I, Taylor MG, Mpourmpakis G, Asplin JR, Rimer JD. Molecular modifiers reveal a mechanism of pathological crystal growth inhibition. Nature. 2016 08 25; 536(7617):446-50. PMID: 27501150.
      View in: PubMed
    30. Knauf F, Thomson RB, Heneghan JF, Jiang Z, Adebamiro A, Thomson CL, Barone C, Asplin JR, Egan ME, Alper SL, Aronson PS. Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion. J Am Soc Nephrol. 2017 Jan; 28(1):242-249. PMID: 27313231.
      View in: PubMed
    31. Alruwaily AF, Dauw CA, Bierlein MJ, Yan P, Asplin JR, Ghani KR, Wolf JS, Hollingsworth JM. How Much Information is Lost When You Only Collect One 24-Hour Urine Sample during the Initial Metabolic Evaluation? J Urol. 2016 Oct; 196(4):1143-8. PMID: 27140069.
      View in: PubMed
    32. Asplin JR. The management of patients with enteric hyperoxaluria. Urolithiasis. 2016 Feb; 44(1):33-43. PMID: 26645872.
      View in: PubMed
    33. Ennis J, Gillen D, Rubenstein A, Worcester E, Brecher ME, Asplin J, Coe F. Clinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: a matched cohort study. BMC Nephrol. 2015 Oct 15; 16:163. PMID: 26471846.
      View in: PubMed
    34. Alruwaily AF, Dauw CA, Bierlein MJ, Asplin JR, Ghani KR, Wolf JS, Hollingsworth JM. Geographic Variation in the Quality of Secondary Prevention for Nephrolithiasis. Urology. 2015 Sep; 86(3):454-8. PMID: 26210006.
      View in: PubMed
    35. Krieger NS, Asplin JR, Frick KK, Granja I, Culbertson CD, Ng A, Grynpas MD, Bushinsky DA. Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria. J Am Soc Nephrol. 2015 Dec; 26(12):3001-8. PMID: 25855777.
      View in: PubMed
    36. DeFoor WR, Asplin JR, Kollar L, Jackson E, Jenkins T, Schulte M, Inge T. Prospective evaluation of urinary metabolic indices in severely obese adolescents after weight loss surgery. Surg Obes Relat Dis. 2016 Feb; 12(2):363-7. PMID: 26077697.
      View in: PubMed
    37. Moorthi RN, Armstrong CL, Janda K, Ponsler-Sipes K, Asplin JR, Moe SM. The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease. Am J Nephrol. 2014; 40(6):582-91. PMID: 25613675.
      View in: PubMed
    38. Dauw CA, Alruwaily AF, Bierlein MJ, Asplin JR, Ghani KR, Wolf JS, Hollingsworth JM. Provider variation in the quality of metabolic stone management. J Urol. 2015 Mar; 193(3):885-90. PMID: 25286012.
      View in: PubMed
    39. Frick KK, Asplin JR, Culbertson CD, Granja I, Krieger NS, Bushinsky DA. Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol. 2014 May 01; 306(9):F1081-7. PMID: 24573387.
      View in: PubMed
    40. Ng AH, Frick KK, Krieger NS, Asplin JR, Cohen-McFarlane M, Culbertson CD, Kyker-Snowman K, Grynpas MD, Bushinsky DA. 1,25(OH)2D3 induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats. Calcif Tissue Int. 2014 May; 94(5):531-43. PMID: 24481706.
      View in: PubMed
    41. Farmanesh S, Ramamoorthy S, Chung J, Asplin JR, Karande P, Rimer JD. Specificity of growth inhibitors and their cooperative effects in calcium oxalate monohydrate crystallization. J Am Chem Soc. 2014 Jan 08; 136(1):367-76. PMID: 24313314.
      View in: PubMed
    42. Frick KK, Asplin JR, Krieger NS, Culbertson CD, Asplin DM, Bushinsky DA. 1,25(OH)2D3-enhanced hypercalciuria in genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol. 2013 Oct 15; 305(8):F1132-8. PMID: 23926184.
      View in: PubMed
    43. Asplin JR, Penniston K, Goldfarb DS. Monosodium urate stones are rare, and urine pH is not low in cystinuria. Am J Kidney Dis. 2013 Jul; 62(1):179-80. PMID: 23773841.
      View in: PubMed
    44. Perry GM, Scheinman SJ, Asplin JR. Effects of Sex on Intra-Individual Variance in Urinary Solutes in Stone-Formers Collected from a Single Clinical Laboratory. PLoS One. 2013; 8(6):e53637. PMID: 23840293.
      View in: PubMed
    45. Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, David RJ, Flavell RA, Aronson PS. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 2013 Nov; 84(5):895-901. PMID: 23739234.
      View in: PubMed
    46. Okonkwo OW, Batwara R, Granja I, Asplin JR, Goldfarb DS. A pilot study of the effect of sodium thiosulfate on urinary lithogenicity and associated metabolic acid load in non-stone formers and stone formers with hypercalciuria. PLoS One. 2013; 8(4):e60380. PMID: 23593205.
      View in: PubMed
    47. Becknell B, Carpenter AR, Bolon B, Asplin JR, Ingraham SE, Hains DS, Schwaderer AL, McHugh KM. Struvite urolithiasis and chronic urinary tract infection in a murine model of urinary diversion. Urology. 2013 May; 81(5):943-8. PMID: 23523293.
      View in: PubMed
    48. Perry GM, Scheinman SJ, Asplin JR. Weight, age and coefficients of variation in renal solute excretion. Nephron Physiol. 2012; 122(1-2):13-8. PMID: 23595094.
      View in: PubMed
    49. Frick KK, Asplin JR, Favus MJ, Culbertson C, Krieger NS, Bushinsky DA. Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats. Am J Physiol Renal Physiol. 2013 Mar 15; 304(6):F718-26. PMID: 23344574.
      View in: PubMed
    50. Asplin DM, Asplin JR. The Interaction of thiol drugs and urine pH in the treatment of cystinuria. J Urol. 2013 Jun; 189(6):2147-51. PMID: 23261477.
      View in: PubMed
    51. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012 Aug; 23(8):1407-15. PMID: 22822075.
      View in: PubMed
    52. Leaf DE, Korets R, Taylor EN, Tang J, Asplin JR, Goldfarb DS, Gupta M, Curhan GC. Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers. Clin J Am Soc Nephrol. 2012 May; 7(5):829-34. PMID: 22422535.
      View in: PubMed
    53. Bergsland KJ, Coe FL, White MD, Erhard MJ, DeFoor WR, Mahan JD, Schwaderer AL, Asplin JR. Urine risk factors in children with calcium kidney stones and their siblings. Kidney Int. 2012 Jun; 81(11):1140-8. PMID: 22358148.
      View in: PubMed
    54. Wu JN, Craig J, Chamie K, Asplin J, Ali MR, Low RK. Urolithiasis risk factors in the bariatric population undergoing gastric bypass surgery. Surg Obes Relat Dis. 2013 Jan-Feb; 9(1):83-7. PMID: 22100051.
      View in: PubMed
    55. Sumorok NT, Asplin JR, Eisner BH, Stoller ML, Goldfarb DS. Effect of diet orange soda on urinary lithogenicity. Urol Res. 2012 Jun; 40(3):237-41. PMID: 21858427.
      View in: PubMed
    56. Mechlin C, Kalorin C, Asplin J, White M. Splenda® improves tolerance of oral potassium citrate supplementation for prevention of stone formation: results of a randomized double-blind trial. J Endourol. 2011 Sep; 25(9):1541-5. PMID: 21815827.
      View in: PubMed
    57. Bushinsky DA, Willett T, Asplin JR, Culbertson C, Che SP, Grynpas M. Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats. J Bone Miner Res. 2011 Aug; 26(8):1904-12. PMID: 21351146.
      View in: PubMed
    58. Maalouf NM, Adams Huet B, Pasch A, Lieske JC, Asplin JR, Siener R, Hesse A, Nuoffer JM, Frey FJ, Knight J, Holmes RP, Zerwekh JE, Bonny O. Variability in urinary oxalate measurements between six international laboratories. Nephrol Dial Transplant. 2011 Dec; 26(12):3954-9. PMID: 21454350.
      View in: PubMed
    59. Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011 Feb; 6(2):257-64. PMID: 21183586.
      View in: PubMed
    60. Bergsland KJ, Zisman AL, Asplin JR, Worcester EM, Coe FL. Evidence for net renal tubule oxalate secretion in patients with calcium kidney stones. Am J Physiol Renal Physiol. 2011 Feb; 300(2):F311-8. PMID: 21123489.
      View in: PubMed
    61. Coe FL, Asplin JR. Medicine. Stopping the stones. Science. 2010 Oct 15; 330(6002):325-6. PMID: 20947749.
      View in: PubMed
    62. Odstrcil EA, Martinez JG, Santa Ana CA, Xue B, Schneider RE, Steffer KJ, Porter JL, Asplin J, Kuhn JA, Fordtran JS. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr. 2010 Oct; 92(4):704-13. PMID: 20739420.
      View in: PubMed
    63. Lambert EH, Asplin JR, Herrell SD, Miller NL. Analysis of 24-hour urine parameters as it relates to age of onset of cystine stone formation. J Endourol. 2010 Jul; 24(7):1179-82. PMID: 20624086.
      View in: PubMed
    64. Eisner BH, Asplin JR, Goldfarb DS, Ahmad A, Stoller ML. Citrate, malate and alkali content in commonly consumed diet sodas: implications for nephrolithiasis treatment. J Urol. 2010 Jun; 183(6):2419-23. PMID: 20403610.
      View in: PubMed
    65. Semins MJ, Asplin JR, Steele K, Assimos DG, Lingeman JE, Donahue S, Magnuson T, Schweitzer M, Matlaga BR. The effect of restrictive bariatric surgery on urinary stone risk factors. Urology. 2010 Oct; 76(4):826-9. PMID: 20381135.
      View in: PubMed
    66. DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010 Jul; 76(1):242-5. PMID: 20110113.
      View in: PubMed
    67. Block GA, Persky MS, Ketteler M, Kestenbaum B, Thadhani R, Kooienga L, Spiegel D, Asplin J, Ehrlich J, Dennis V, Nissenson A, Chertow GM, Wheeler DC. A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodial Int. 2009 Jul; 13(3):360-2. PMID: 19601992.
      View in: PubMed
    68. Asplin JR, Donahue SE, Lindeman C, Michalenka A, Strutz KL, Bushinsky DA. Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol. 2009 Jun; 20(6):1246-53. PMID: 19369406.
      View in: PubMed
    69. Patel V, Nicar M, Emmett M, Asplin J, Maguire JA, Santa Ana CA, Fordtran JS. Intestinal and renal effects of low-volume phosphate and sulfate cathartic solutions designed for cleansing the colon: pathophysiological studies in five normal subjects. Am J Gastroenterol. 2009 Apr; 104(4):953-65. PMID: 19240703.
      View in: PubMed
    70. Asplin JR. Obesity and urolithiasis. Adv Chronic Kidney Dis. 2009 Jan; 16(1):11-20. PMID: 19095201.
      View in: PubMed
    71. Goodman JW, Asplin JR, Goldfarb DS. Effect of two sports drinks on urinary lithogenicity. Urol Res. 2009 Feb; 37(1):41-6. PMID: 19066876.
      View in: PubMed
    72. Patel BN, Passman CM, Fernandez A, Asplin JR, Coe FL, Kim SC, Lingeman JE, Assimos DG. Prevalence of hyperoxaluria after bariatric surgery. J Urol. 2009 Jan; 181(1):161-6. PMID: 19013593.
      View in: PubMed
    73. Pramanik R, Asplin JR, Jackson ME, Williams JC. Protein content of human apatite and brushite kidney stones: significant correlation with morphologic measures. Urol Res. 2008 Oct; 36(5):251-8. PMID: 18779958.
      View in: PubMed
    74. DeFoor W, Minevich E, Jackson E, Reddy P, Clark C, Sheldon C, Asplin J. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008 Jun; 179(6):2369-72. PMID: 18433777.
      View in: PubMed
    75. Asplin JR. Evaluation of the kidney stone patient. Semin Nephrol. 2008 Mar; 28(2):99-110. PMID: 18359391.
      View in: PubMed
    76. Asplin JR. Nephrolithiasis: introduction. Semin Nephrol. 2008 Mar; 28(2):97-8. PMID: 18359390.
      View in: PubMed
    77. Bushinsky DA, Michalenka AC, Strutz KL, Donahue S, Asplin JR. Effect of bolus and divided feeding on urine ions and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int. 2008 Feb; 73(4):423-9. PMID: 18046318.
      View in: PubMed
    78. Goldfarb DS, Modersitzki F, Asplin JR. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol. 2007 Jul; 2(4):745-9. PMID: 17699491.
      View in: PubMed
    79. Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007 Feb; 177(2):565-9. PMID: 17222634.
      View in: PubMed
    80. DeFoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Erhard M, Minevich E. Urinary metabolic evaluations in normal and stone forming children. J Urol. 2006 Oct; 176(4 Pt 2):1793-6. PMID: 16945651.
      View in: PubMed
    81. Asplin JR, Donahue S, Kinder J, Coe FL. Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int. 2006 Oct; 70(8):1463-7. PMID: 16941029.
      View in: PubMed
    82. Bushinsky DA, Laplante K, Asplin JR. Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int. 2006 May; 69(9):1586-92. PMID: 16557225.
      View in: PubMed
    83. Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet. 2006 Apr; 38(4):474-8. PMID: 16532010.
      View in: PubMed
    84. Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. 2006 Mar; 69(6):1041-7. PMID: 16501494.
      View in: PubMed
    85. Wolf J, Asplin JR, Goldfarb DS. Chitosan does not reduce post-prandial urinary oxalate excretion. Urol Res. 2006 Aug; 34(4):227-30. PMID: 16506035.
      View in: PubMed
    86. Defoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Minevich E. Results of a prospective trial to compare normal urine supersaturation in children and adults. J Urol. 2005 Oct; 174(4 Pt 2):1708-10. PMID: 16148687.
      View in: PubMed
    87. Dolin DJ, Asplin JR, Flagel L, Grasso M, Goldfarb DS. Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol. 2005 Apr; 19(3):429-32. PMID: 15865542.
      View in: PubMed
    88. Bushinsky DA, Asplin JR. Thiazides reduce brushite, but not calcium oxalate, supersaturation, and stone formation in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol. 2005 Feb; 16(2):417-24. PMID: 15647340.
      View in: PubMed
    89. Pramanik R, Asplin JR, Lindeman C, Favus MJ, Bai S, Coe FL. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Cell Immunol. 2004 Nov-Dec; 232(1-2):137-43. PMID: 15876428.
      View in: PubMed
    90. Asplin JR, Bauer KA, Kinder J, Müller G, Coe BJ, Parks JH, Coe FL. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int. 2003 Feb; 63(2):662-9. PMID: 12631132.
      View in: PubMed
    91. Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002 Dec; 31(4):927-49. PMID: 12474639.
      View in: PubMed
    92. Raja KA, Schurman S, D'mello RG, Blowey D, Goodyer P, Van Why S, Ploutz-Snyder RJ, Asplin J, Scheinman SJ. Responsiveness of hypercalciuria to thiazide in Dent's disease. J Am Soc Nephrol. 2002 Dec; 13(12):2938-44. PMID: 12444212.
      View in: PubMed
    93. Bergsland KJ, Kinder JM, Asplin JR, Coe BJ, Coe FL. Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients. J Urol. 2002 Jun; 167(6):2372-6. PMID: 11992040.
      View in: PubMed
    94. Kinder JM, Clark CD, Coe BJ, Asplin JR, Parks JH, Coe FL. Urinary stone risk factors in the siblings of patients with calcium renal stones. J Urol. 2002 May; 167(5):1965-7. PMID: 11956418.
      View in: PubMed
    95. Asplin JR, Parks JH, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int. 2002 May; 61(5):1821-9. PMID: 11967033.
      View in: PubMed
    96. Parks JH, Goldfisher E, Asplin JR, Coe FL. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol. 2002 Apr; 167(4):1607-12. PMID: 11912373.
      View in: PubMed
    97. Bushinsky DA, Asplin JR, Grynpas MD, Evan AP, Parker WR, Alexander KM, Coe FL. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int. 2002 Mar; 61(3):975-87. PMID: 11849452.
      View in: PubMed
    98. Parks JH, Asplin JR, Coe FL. Patient adherence to long-term medical treatment of kidney stones. J Urol. 2001 Dec; 166(6):2057-60. PMID: 11696706.
      View in: PubMed
    99. Coe FL, Wise H, Parks JH, Asplin JR. Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol. 2001 Oct; 166(4):1247-51. PMID: 11547051.
      View in: PubMed
    100. Coe FL, Wise H, Parks JH, Fleury PJ, Asplin JR. Differences in urine volume and supersaturation in 2 physician networks. J Urol. 2001 Aug; 166(2):423-8. PMID: 11458041.
      View in: PubMed
    101. Coe FL, Clark C, Parks JH, Asplin JR. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol. 2001 Aug; 166(2):688-93. PMID: 11458118.
      View in: PubMed
    102. Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int. 2001 Jul; 60(1):77-82. PMID: 11422738.
      View in: PubMed
    103. Goldfarb DS, Asplin JR. Effect of grapefruit juice on urinary lithogenicity. J Urol. 2001 Jul; 166(1):263-7. PMID: 11435883.
      View in: PubMed
    104. Bushinsky DA, Grynpas MD, Asplin JR. Effect of acidosis on urine supersaturation and stone formation in genetic hypercalciuric stone-forming rats. Kidney Int. 2001 Apr; 59(4):1415-23. PMID: 11260403.
      View in: PubMed
    105. Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL. Clinical use of cystine supersaturation measurements. J Urol. 2000 Nov; 164(5):1481-5. PMID: 11025687.
      View in: PubMed
    106. Lam GS, Asplin JR, Halperin ML. Does a high concentration of calcium in the urine cause an important renal concentrating defect in human subjects? Clin Sci (Lond). 2000 Mar; 98(3):313-9. PMID: 10677390.
      View in: PubMed
    107. Bushinsky DA, Parker WR, Asplin JR. Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats. Kidney Int. 2000 Feb; 57(2):550-60. PMID: 10652032.
      View in: PubMed
    108. Scheinman SJ, Cox JP, Lloyd SE, Pearce SH, Salenger PV, Hoopes RR, Bushinsky DA, Wrong O, Asplin JR, Langman CB, Norden AG, Thakker RV. Isolated hypercalciuria with mutation in CLCN5: relevance to idiopathic hypercalciuria. Kidney Int. 2000 Jan; 57(1):232-9. PMID: 10620204.
      View in: PubMed
    109. Asplin JR, Parks JH, Chen MS, Lieske JC, Toback FG, Pillay SN, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int. 1999 Oct; 56(4):1505-16. PMID: 10504502.
      View in: PubMed
    110. Lingeman J, Kahnoski R, Mardis H, Goldfarb DS, Grasso M, Lacy S, Scheinman SJ, Asplin JR, Parks JH, Coe FL. Divergence between stone composition and urine supersaturation: clinical and laboratory implications. J Urol. 1999 Apr; 161(4):1077-81. PMID: 10081841.
      View in: PubMed
    111. Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999 Jan; 55(1):234-43. PMID: 9893132.
      View in: PubMed
    112. Lingeman J, Mardis H, Kahnoski R, Goldfarb DS, Lacy S, Grasso M, Scheinman SJ, Parks JH, Asplin JR, Coe FL. Medical reduction of stone risk in a network of treatment centers compared to a research clinic. J Urol. 1998 Nov; 160(5):1629-34. PMID: 9783920.
      View in: PubMed
    113. Pillay SN, Asplin JR, Coe FL. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol. 1998 08; 275(2):F255-61. PMID: 9691016.
      View in: PubMed
    114. Asplin J, Parks J, Lingeman J, Kahnoski R, Mardis H, Lacey S, Goldfarb D, Grasso M, Coe F. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol. 1998 Jun; 159(6):1821-5. PMID: 9598467.
      View in: PubMed
    115. Asplin JR, Lingeman J, Kahnoski R, Mardis H, Parks JH, Coe FL. Metabolic urinary correlates of calcium oxalate dihydrate in renal stones. J Urol. 1998 Mar; 159(3):664-8. PMID: 9474121.
      View in: PubMed
    116. Asplin JR, Arsenault D, Parks JH, Coe FL, Hoyer JR. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 1998 Jan; 53(1):194-9. PMID: 9453018.
      View in: PubMed
    117. Asplin JR, Parks JH, Coe FL. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int. 1997 Dec; 52(6):1602-8. PMID: 9407506.
      View in: PubMed
    118. Asplin JR, Bushinsky DA, Singharetnam W, Riordon D, Parks JH, Coe FL. Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int. 1997 Mar; 51(3):640-5. PMID: 9067894.
      View in: PubMed
    119. Asplin JR. Uric acid stones. Semin Nephrol. 1996 Sep; 16(5):412-24. PMID: 8890397.
      View in: PubMed
    120. Porile JL, Asplin JR, Parks JH, Nakagawa Y, Coe FL. Normal calcium oxalate crystal growth inhibition in severe calcium oxalate nephrolithiasis. J Am Soc Nephrol. 1996 Apr; 7(4):602-7. PMID: 8724894.
      View in: PubMed
    121. Asplin JR, Mandel NS, Coe FL. Evidence of calcium phosphate supersaturation in the loop of Henle. Am J Physiol. 1996 Apr; 270(4 Pt 2):F604-13. PMID: 8967338.
      View in: PubMed
    122. Coe FL, Nakagawa Y, Asplin J, Parks JH. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab. 1994; 20(6):378-84. PMID: 7783700.
      View in: PubMed
    123. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992 Oct 15; 327(16):1141-52. PMID: 1528210.
      View in: PubMed
    124. Asplin J, DeGanello S, Nakagawa YN, Coe FL. Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol. 1991 Nov; 261(5 Pt 2):F824-30. PMID: 1951713.
      View in: PubMed
    Asplin's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (374) concept(s)
    _
    Co-Authors Expand Description
    See all (10) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _